Genmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by HC Wainwright

Share on StockTwits

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report published on Monday morning, AnalystRatings.com reports. HC Wainwright currently has a $24.00 target price on the stock.

“We use a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 8.0% discount rate and 23% effective tax rate. We assign a 90% probability of approval to DARZALEX in smoldering MM; a 95% probability to ARZERRA in relapsing-remitting multiple sclerosis (RR-MS); an 85% probability to teprotumumab; a 20% probability to enapotamab vedotin in 35% probabilities of approval to tisotumab vedotin for cervical cancer and ovarian cancer, respectively.”,” the firm’s analyst wrote.

Several other equities analysts have also commented on GMAB. Bank of America upgraded Genmab A/S from a neutral rating to a buy rating in a research note on Friday, September 13th. Morgan Stanley assumed coverage on Genmab A/S in a research note on Monday, August 12th. They set an overweight rating on the stock. Guggenheim assumed coverage on Genmab A/S in a research note on Monday, August 12th. They set a buy rating on the stock. Royal Bank of Canada assumed coverage on Genmab A/S in a research note on Monday, August 12th. They set an outperform rating and a $23.00 price target on the stock. Finally, JPMorgan Chase & Co. upgraded Genmab A/S from a neutral rating to an overweight rating and set a $23.00 price target on the stock in a research note on Thursday, September 12th. Six research analysts have rated the stock with a buy rating, Genmab A/S presently has an average rating of Buy and an average price target of $23.33.

Shares of Genmab A/S stock opened at $20.49 on Monday. Genmab A/S has a 12 month low of $12.10 and a 12 month high of $21.45. The company’s fifty day moving average price is $19.86.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, August 14th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.07 by $0.13. The firm had revenue of $116.49 million for the quarter. As a group, analysts forecast that Genmab A/S will post 0.41 EPS for the current year.

An institutional investor recently bought a new position in Genmab A/S stock. Private Capital Group LLC purchased a new stake in shares of Genmab A/S (NASDAQ:GMAB) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,680 shares of the company’s stock, valued at approximately $41,000. Hedge funds and other institutional investors own 0.83% of the company’s stock.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Recommended Story: Short Selling

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Civic  Market Cap Achieves $26.92 Million
Civic Market Cap Achieves $26.92 Million
TRAXIA Tops 24-Hour Trading Volume of $207.00
TRAXIA Tops 24-Hour Trading Volume of $207.00
TOP  Price Hits $0.0022
TOP Price Hits $0.0022
Syndax Pharmaceuticals  Stock Rating Upgraded by Zacks Investment Research
Syndax Pharmaceuticals Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America  Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America Stock Rating Upgraded by Zacks Investment Research
Renewable Energy Group  Rating Increased to Hold at Zacks Investment Research
Renewable Energy Group Rating Increased to Hold at Zacks Investment Research


 
© 2006-2019 Zolmax.